Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Best Practices, LLC
Report suggests early-stage market research and analytics in oncology increases chance of success
June 23rd, 2006
More biopharmaceutical companies are turning to market research earlier in the drug development phase to ensure that projections and research are on target towards producing viable and profitable drugs. For instance, 88% of benchmarked companies commission market research as early as Phase I while a vast majority - 64% of research participants - invest in market research at the preclinical stage, according to a research by the life sciences benchmarking firm Best Practices, LLC. Previous Best Practices research found that only one-third of biopharmaceutical companies generally invested in market research at the pre-clinical stage for general...
Source: Biotech Law Weekly (2006-06-23)
|
